See more : Keppel DC REIT (KPDCF) Income Statement Analysis – Financial Results
Complete financial analysis of Apyx Medical Corporation (APYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apyx Medical Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- GlobalData Plc (YK6B.F) Income Statement Analysis – Financial Results
- Japan Airport Terminal Co., Ltd. (JTTRY) Income Statement Analysis – Financial Results
- Amira Nature Foods Ltd. (ANFIF) Income Statement Analysis – Financial Results
- The Walt Disney Company (WDP.DE) Income Statement Analysis – Financial Results
- Pampa Metals Corporation (PMMCF) Income Statement Analysis – Financial Results
Apyx Medical Corporation (APYX)
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.35M | 44.51M | 48.52M | 27.71M | 28.15M | 16.69M | 38.88M | 36.63M | 29.52M | 27.68M | 23.66M | 27.67M | 25.41M | 24.23M | 26.95M | 28.10M | 28.78M | 26.68M | 20.21M | 20.50M | 16.55M | 12.45M | 11.48M | 9.94M | 9.60M | 8.44M | 7.37M | 7.49M | 5.52M |
| Cost of Revenue | 18.59M | 15.38M | 14.92M | 10.21M | 9.03M | 5.89M | 19.12M | 18.71M | 16.96M | 18.69M | 14.46M | 16.34M | 14.68M | 14.24M | 15.10M | 16.25M | 17.46M | 16.08M | 12.65M | 12.51M | 9.43M | 7.19M | 5.72M | 4.60M | 4.59M | 5.27M | 4.14M | 4.13M | 3.22M |
| Gross Profit | 33.76M | 29.13M | 33.60M | 17.50M | 19.13M | 10.79M | 19.76M | 17.92M | 12.56M | 8.99M | 9.20M | 11.33M | 10.73M | 9.99M | 11.85M | 11.85M | 11.32M | 10.60M | 7.56M | 7.98M | 7.12M | 5.26M | 5.76M | 5.34M | 5.01M | 3.17M | 3.23M | 3.35M | 2.31M |
| Gross Profit Ratio | 64.49% | 65.45% | 69.26% | 63.17% | 67.94% | 64.68% | 50.82% | 48.91% | 42.54% | 32.48% | 38.88% | 40.96% | 42.23% | 41.22% | 43.98% | 42.17% | 39.32% | 39.74% | 37.41% | 38.94% | 43.00% | 42.23% | 50.15% | 53.74% | 52.19% | 37.53% | 43.85% | 44.77% | 41.76% |
| Research & Development | 4.84M | 4.54M | 4.32M | 3.92M | 3.81M | 2.47M | 2.46M | 2.62M | 2.16M | 1.42M | 1.26M | 1.33M | 1.20M | 1.85M | 2.08M | 2.06M | 1.64M | 1.19M | 985.81K | 907.39K | 717.35K | 693.71K | 463.13K | 513.02K | 379.83K | 183.17K | 96.74K | 105.70K | 121.90K |
| General & Administrative | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 2.30M | 1.30M | 800.00K | 1.50M | 800.00K | 11.37M | 8.57M | 8.42M | 6.69M | 4.89M | 4.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 8.50M | 7.57M | 6.79M | 6.01M | 5.76M | 5.60M | 4.91M | 4.71M | 3.90M | 6.46M | 1.75M | 0.00 | 1.34M | 1.18M |
| Other Expenses | 0.00 | 509.00K | -373.00K | 479.00K | -382.00K | -203.00K | -11.37M | -8.57M | -8.42M | -6.69M | -4.89M | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 161.19K | 39.29K | 81.91K | 124.45K | 0.00 | 396.81K | 321.17K | 2.15M | 2.80M | 1.43M | 1.22M |
| Operating Expenses | 51.02M | 52.69M | 48.05M | 37.59M | 40.04M | 23.65M | 23.50M | 21.71M | 19.54M | 14.84M | 11.22M | 10.29M | 11.50M | 11.45M | 11.14M | 10.56M | 9.21M | 7.98M | 7.16M | 6.70M | 6.40M | 5.73M | 5.18M | 4.81M | 7.16M | 4.09M | 2.89M | 2.87M | 2.53M |
| Cost & Expenses | 69.61M | 68.07M | 62.97M | 47.79M | 49.07M | 29.55M | 42.62M | 40.42M | 36.51M | 33.53M | 25.69M | 26.63M | 26.18M | 25.70M | 26.24M | 26.81M | 26.67M | 24.05M | 19.81M | 19.22M | 15.84M | 12.92M | 10.90M | 9.41M | 11.75M | 9.36M | 7.03M | 7.01M | 5.74M |
| Interest Income | 921.00K | 157.00K | 11.00K | 241.00K | 1.39M | 616.00K | 0.00 | 0.00 | 1.00K | 0.00 | 7.00K | 0.00 | 12.00K | 0.00 | 24.36K | 48.76K | 142.72K | 103.09K | 46.96K | 3.26K | 2.98K | 5.21K | 10.11K | 28.75K | 0.00 | 4.16K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.48M | 15.00K | 10.00K | 46.00K | 8.00K | 104.00K | 136.00K | 158.00K | 158.00K | 151.00K | 237.00K | 232.00K | 249.00K | 223.00K | 76.37K | 58.46K | 2.47K | 16.16K | 22.70K | 15.09K | 34.06K | 48.45K | 70.69K | 66.80K | 0.00 | 103.84K | 0.00 | 75.80K | 68.70K |
| Depreciation & Amortization | 692.00K | 890.00K | 903.00K | 887.00K | 754.00K | 669.00K | 696.00K | 734.00K | 812.00K | 876.00K | 827.00K | 857.00K | 925.00K | 1.01M | 1.05M | 973.07K | 770.83K | 529.26K | 545.88K | 395.12K | 314.68K | 274.88K | 524.24K | 396.81K | 321.17K | 787.09K | 311.14K | 260.60K | 171.00K |
| EBITDA | -18.11M | -22.01M | -13.91M | -18.48M | -19.07M | -13.92M | -13.01M | -3.79M | -4.37M | -12.25M | -3.68M | 1.93M | 1.19M | -1.23M | 1.79M | 3.81M | 2.88M | 3.15M | 949.84K | 1.67M | 978.14K | -199.02K | 1.16M | 926.71K | 947.21K | -133.07K | 650.72K | 741.00K | -48.50K |
| EBITDA Ratio | -34.60% | -51.44% | -30.53% | -69.87% | -70.69% | -78.28% | -9.62% | -10.35% | -23.67% | -21.13% | -10.17% | 6.88% | 3.62% | 1.29% | 6.64% | 2.74% | 10.00% | 11.82% | 4.70% | 8.17% | 6.70% | -0.62% | 9.21% | 9.24% | -19.07% | -1.83% | 8.36% | 9.75% | -1.92% |
| Operating Income | -17.26M | -23.56M | -14.45M | -20.08M | -20.91M | -13.60M | -5.27M | -3.79M | -6.99M | -5.85M | -3.67M | 1.05M | -18.00K | -2.75M | 714.85K | 1.29M | 2.11M | 2.62M | 403.97K | 1.28M | 712.40K | -473.90K | 583.58K | 529.90K | -2.15M | -920.16K | 339.58K | 480.40K | -219.50K |
| Operating Income Ratio | -32.97% | -52.94% | -29.78% | -72.47% | -74.28% | -81.51% | -13.54% | -10.35% | -23.67% | -21.13% | -15.49% | 3.78% | -0.07% | -11.36% | 2.65% | 4.60% | 7.32% | 9.84% | 2.00% | 6.24% | 4.30% | -3.81% | 5.08% | 5.33% | -22.38% | -10.90% | 4.61% | 6.42% | -3.98% |
| Total Other Income/Expenses | -4.02M | 651.00K | -372.00K | 674.00K | 1.03M | -1.09M | -8.57M | -94.00K | 1.64M | -7.44M | -2.29M | -212.00K | 50.00K | 290.00K | -52.01K | 1.49M | 140.25K | 86.93K | 24.26K | -11.83K | -31.08K | -40.87K | -431.47K | 8.79K | 3.25K | -77.88K | -240.39K | -64.80K | 65.40K |
| Income Before Tax | -21.28M | -22.91M | -14.82M | -19.41M | -19.91M | -13.27M | -5.22M | -3.89M | -5.35M | -13.29M | -5.95M | 834.00K | 32.00K | -2.46M | 662.84K | 2.78M | 2.25M | 2.71M | 428.22K | 1.27M | 681.32K | -514.77K | 200.59K | 538.69K | -2.14M | -998.05K | 99.19K | 415.60K | -154.10K |
| Income Before Tax Ratio | -40.65% | -51.47% | -30.55% | -70.04% | -70.72% | -79.53% | -13.42% | -10.61% | -18.11% | -47.99% | -25.16% | 3.01% | 0.13% | -10.16% | 2.46% | 9.88% | 7.81% | 10.16% | 2.12% | 6.18% | 4.12% | -4.14% | 1.75% | 5.42% | -22.35% | -11.82% | 1.35% | 5.55% | -2.79% |
| Income Tax Expense | -2.43M | 367.00K | 380.00K | -7.50M | -260.00K | -3.78M | -156.00K | 64.00K | 25.00K | 4.00M | -1.61M | 217.00K | -77.00K | -927.00K | 67.32K | 945.42K | -148.84K | 47.57K | 32.02K | -272.72K | 31.08K | 40.87K | -211.19K | 29.27K | 35.81K | 77.88K | 240.39K | 8.30K | -65.40K |
| Net Income | -18.71M | -23.28M | -15.20M | -11.91M | -19.65M | 64.01M | -5.06M | -3.95M | -5.37M | -17.28M | -4.34M | 617.00K | 109.00K | -1.54M | 595.52K | 1.83M | 2.40M | 2.68M | 406.21K | 1.51M | 681.32K | -514.77K | 784.29K | 500.63K | -2.18M | -998.05K | 99.19K | 407.30K | -154.10K |
| Net Income Ratio | -35.75% | -52.30% | -31.33% | -42.96% | -69.79% | 383.61% | -13.02% | -10.78% | -18.19% | -62.43% | -18.34% | 2.23% | 0.43% | -6.34% | 2.21% | 6.52% | 8.34% | 10.06% | 2.01% | 7.38% | 4.12% | -4.14% | 6.83% | 5.04% | -22.75% | -11.82% | 1.35% | 5.44% | -2.79% |
| EPS | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.93 | -0.16 | -0.14 | -0.22 | -0.98 | -0.25 | 0.04 | 0.01 | -0.09 | 0.04 | 0.11 | 0.15 | 0.19 | 0.03 | 0.11 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
| EPS Diluted | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.86 | -0.16 | -0.14 | -0.19 | -0.97 | -0.25 | 0.03 | 0.01 | -0.09 | 0.03 | 0.11 | 0.13 | 0.16 | 0.03 | 0.09 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
| Weighted Avg Shares Out | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 33.19M | 31.42M | 27.43M | 24.33M | 17.68M | 17.49M | 17.63M | 17.60M | 17.37M | 16.90M | 16.07M | 15.32M | 14.54M | 13.92M | 13.75M | 13.63M | 13.20M | 13.45M | 13.90M | 13.88M | 13.88M | 8.19M | 7.66M | 4.35M |
| Weighted Avg Shares Out (Dil) | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 34.37M | 31.43M | 27.45M | 27.75M | 17.76M | 17.67M | 17.79M | 17.67M | 17.37M | 17.84M | 17.09M | 17.68M | 16.91M | 15.75M | 16.80M | 13.63M | 14.41M | 14.76M | 16.07M | 13.88M | 13.88M | 8.44M | 7.66M | 4.35M |
Apyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2022, and updated financial expectations for...
Apyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2022, and updated financial expectations for...
Apyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2022, and updated financial expectations for...
APYX SHAREHOLDER ALERT: Jakubowitz Law Reminds Apyx Shareholders of a Lead Plaintiff Deadline of August 5, 2022
NEW YORK , Aug. 5, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX). To receive updates on the lawsuit, fill out the form:...
Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Apyx Medical Corporation (APYX) Investors of Class Action and Last Few Hours to Actively Participate
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) and certain of its officers, on behalf of all persons and entities...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - August 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ: APYX) for violations of §§10(b)...
Apyx Class Action: Levi & Korsinsky Reminds Apyx Medical Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2022 - APYX
New York, New York--(Newsfile Corp. - August 4, 2022) - Levi & Korsinsky, LLP notifies investors in Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") of a class action securities lawsuit.The lawsuit on behalf of Apyx investors has been...
APYX DEADLINE TOMORROW: ROSEN, A TOP RANKED FIRM, Encourages Apyx Medical Corporation Investors With Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - APYX
New York, New York--(Newsfile Corp. - August 4, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation (APYX)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Apyx Medical Corporation (“Apyx” or...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation (APYX)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Apyx Medical Corporation (“Apyx” or...
Source: https://incomestatements.info
Category: Stock Reports